Valeo Financial Advisors LLC Sells 29,989 Shares of AbbVie Inc. $ABBV

Valeo Financial Advisors LLC trimmed its position in AbbVie Inc. (NYSE:ABBV) by 36.0% during the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 53,285 shares of the company’s stock after selling 29,989 shares during the quarter. Valeo Financial Advisors LLC’s holdings in AbbVie were worth $9,891,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also added to or reduced their stakes in the company. Brighton Jones LLC lifted its holdings in AbbVie by 17.4% in the 4th quarter. Brighton Jones LLC now owns 22,912 shares of the company’s stock worth $4,072,000 after buying an additional 3,401 shares during the period. Revolve Wealth Partners LLC raised its holdings in shares of AbbVie by 72.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 7,279 shares of the company’s stock valued at $1,294,000 after acquiring an additional 3,064 shares in the last quarter. Steward Partners Investment Advisory LLC lifted its stake in AbbVie by 0.7% in the first quarter. Steward Partners Investment Advisory LLC now owns 272,085 shares of the company’s stock worth $57,007,000 after acquiring an additional 1,907 shares during the period. LeConte Wealth Management LLC bought a new stake in AbbVie in the first quarter valued at $292,000. Finally, Ethos Financial Group LLC boosted its holdings in AbbVie by 311.0% in the first quarter. Ethos Financial Group LLC now owns 11,306 shares of the company’s stock valued at $2,281,000 after acquiring an additional 8,555 shares in the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

Several brokerages have commented on ABBV. BMO Capital Markets upped their price objective on shares of AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a report on Friday, September 12th. JPMorgan Chase & Co. increased their price target on shares of AbbVie from $250.00 to $260.00 and gave the stock an “overweight” rating in a research note on Monday, November 3rd. Wells Fargo & Company raised their price objective on shares of AbbVie from $240.00 to $260.00 and gave the stock an “overweight” rating in a report on Friday, September 12th. Citigroup reduced their target price on AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a report on Monday, November 3rd. Finally, HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and raised their target price for the company from $225.00 to $265.00 in a research note on Wednesday. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and eight have given a Hold rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $244.55.

AbbVie Stock Performance

Shares of ABBV opened at $223.45 on Monday. The company has a quick ratio of 0.60, a current ratio of 0.72 and a debt-to-equity ratio of 44.14. The stock has a market cap of $394.92 billion, a P/E ratio of 169.28, a P/E/G ratio of 1.21 and a beta of 0.36. The business’s 50 day moving average price is $227.25 and its 200-day moving average price is $209.95. AbbVie Inc. has a 52 week low of $164.39 and a 52 week high of $244.81.

AbbVie (NYSE:ABBV) last posted its quarterly earnings data on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The company had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.58 billion. During the same quarter last year, the company earned $3.00 EPS. The firm’s revenue for the quarter was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Equities research analysts anticipate that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

AbbVie Increases Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. This is a boost from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 annualized dividend and a dividend yield of 3.1%. The ex-dividend date is Friday, January 16th. AbbVie’s payout ratio is currently 496.97%.

AbbVie Profile

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.